Treventis founders awarded funding for COVID-19 clinical trial

LifeArc, a major UK-based charity, has announced funding for Treventis founders Dr. Donald Weaver, Christopher Barden, and Mark Reed to perform a repurposing clinical trial in inhaled furosemide for patients on mechanical ventilation due to COVID-19.

This funding, awarded through a highly competitive rapid-response process starting on March 30, was awarded on Jun 30.  This “Furosemide as Supportive Therapy (FaST)” study is a multi-center trial at University Health Network, Kingston General Hospital, and other sites throughout Canada. The rationale for this approach, which involves the repurposing of a cheap and highly available generic, comes from a serendipitous finding about furosemide in Dr. Weaver’s groundbreaking neuroinflammation research (for which he was named a Harrington Scholar-Innovator in December 2019).

Further information about this approach is summarized in The American Journal of the Medical Sciences and a recent publication in PeerJ.

Treventis congratulates these founders on their discovery and wishes them success in a very timely and important area of research.

Share this page

#pf-body .pf-caption img.blockImage { margin: 0!important; float: none; } #pf-body a.elementor-icon, #pf-body a.skip-link{display:none!important;} /*#pf-content {max-width:100%!important}*/ #pf-content img.mediumImage, #pf-content figure.mediumImage { margin-left: auto!important; margin-right: auto!important; clear: both!important; float: none!important; display: block!important; }